Moleculin Biotech (MBRX) Non-Current Assets (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Non-Current Assets of $12.4 million for Q4 2025, up 6.04% year-over-year from $11.7 million in Q4 2024, and little changed quarter-over-quarter from $12.5 million in Q3 2025.
Moleculin Biotech (MBRX) Non-Current Assets (2016 - 2026) Analysis & Trends
Moleculin Biotech's Non-Current Assets history runs 10 years deep, the most recent figure standing at $12.4 million for Q4 2025.
- In Q4 2025, Non-Current Assets rose 6.04% year-over-year to $12.4 million; the TTM figure through Dec 2025 stood at $49.1 million (up 3.91% YoY), while the FY2025 annual figure was $12.4 million, up 6.04% from the prior year.
- Non-Current Assets for Q4 2025 stood at $12.4 million, roughly flat from $12.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $12.5 million in Q2 2025, with the low at $11.5 million in Q1 2022.
- The 5-year median for Non-Current Assets is $11.8 million (2022), against an average of $11.9 million.
- The sharpest annual moves came in 2021 and 2025: Non-Current Assets slipped 2.2% in 2021, then climbed 6.04% in 2025.
- Moleculin Biotech's Non-Current Assets stood at $11.6 million in 2021, then grew by 2.01% to $11.8 million in 2022, then increased by 1.0% to $11.9 million in 2023, then fell by 1.78% to $11.7 million in 2024, then gained by 6.04% to $12.4 million in 2025.
- Business Quant data shows MBRX's Non-Current Assets at $12.4 million in Q4 2025, $12.5 million in Q3 2025, and $12.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | 12.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.36 Mn |
| Dec 31, 2025 | 12.44 Mn |
| Sep 30, 2025 | 12.47 Mn |
| Jun 30, 2025 | 12.52 Mn |
| Mar 31, 2025 | 11.67 Mn |
| Dec 31, 2024 | 11.73 Mn |
| Sep 30, 2024 | 11.79 Mn |
| Jun 30, 2024 | 11.84 Mn |
| Mar 31, 2024 | 11.89 Mn |
| Dec 31, 2023 | 11.94 Mn |
| Sep 30, 2023 | 11.92 Mn |
| Jun 30, 2023 | 11.74 Mn |
| Mar 31, 2023 | 11.77 Mn |
| Dec 31, 2022 | 11.83 Mn |
| Sep 30, 2022 | 11.88 Mn |
| Jun 30, 2022 | 11.93 Mn |
| Mar 31, 2022 | 11.54 Mn |
| Dec 31, 2021 | 11.59 Mn |
| Sep 30, 2021 | 11.63 Mn |
| Jun 30, 2021 | 11.70 Mn |